Global Quetiapine Market Size By Type (Immediate Release Tablets, Extended Release Tablets), By Application (Adult, Old Man), By Region, And Segment Forecasts, 2023 to 2032

The Global Quetiapine Market was valued at USD 7.1 billion in 2023 and is projected to reach USD 11.4 billion by 2031, growing at a CAGR of 6.1% during the forecast period of 2023–2031. Quetiapine, a widely used atypical antipsychotic, is primarily prescribed for the treatment of schizophrenia, bipolar disorder, and major depressive disorder (as an adjunct therapy). The market is experiencing steady growth driven by the rising prevalence of mental health disorders, increasing acceptance of long-term antipsychotic treatments, and the expanding geriatric population vulnerable to such conditions. The development of extended-release formulations and growing awareness of psychiatric illnesses in developing regions are also contributing significantly to market expansion.

Drivers:

1. Rising Prevalence of Mental Health Disorders:

An increasing global burden of mental health conditions such as schizophrenia, bipolar disorder, and major depressive disorder is the primary growth driver. Quetiapine is widely prescribed due to its efficacy, relatively favorable side effect profile, and approval for multiple indications.

2. Expanding Geriatric Population:

Older adults are more susceptible to psychotic and mood disorders. With the global aging population, the demand for safe and effective antipsychotic treatments like quetiapine is rising.

3. Increase in Off-label Use:

Quetiapine is frequently used off-label for treating insomnia, anxiety, and PTSD. This broader clinical application, though controversial, has boosted market demand.

Restraints:

1. Patent Expiry and Generic Competition:

The loss of patent exclusivity has led to a significant influx of generic versions, reducing prices and limiting revenue growth for brand manufacturers.

2. Side Effects and Black Box Warnings:

The drug's association with weight gain, metabolic syndrome, and increased mortality risk in elderly dementia patients, along with FDA black box warnings, restricts its use in certain populations.

Opportunity:

1. Growth in Emerging Markets:

Countries in Asia-Pacific and Latin America are seeing improved healthcare access and rising mental health awareness, offering untapped growth potential for quetiapine formulations.

2. Development of Extended-release and Low-dose Formulations:

Innovations in delivery formats aimed at improving adherence and reducing side effects are creating opportunities for branded players to retain market share despite generic erosion.

Market by System Type Insights:

Based on system type, the Extended-Release (XR) segment accounted for the largest share in 2023. XR formulations offer better compliance due to once-daily dosing and reduced side effects, making them favorable among clinicians and patients. The Immediate-Release (IR) segment, while still in use, is experiencing slower growth due to higher fluctuation in blood concentration and associated side effects.

Market by End-use Insights:

By end-use, the Hospital Pharmacies segment dominated the market in 2023, owing to the higher prescription rate of quetiapine in inpatient psychiatric care settings. The Retail Pharmacies segment follows closely, driven by the high prevalence of outpatient treatment plans and chronic nature of disorders treated by quetiapine.

Market by Regional Insights:

North America held the largest market share in 2023, driven by a high prevalence of mental illnesses, well-established healthcare infrastructure, and favorable reimbursement policies. Asia-Pacific is expected to witness the fastest growth during the forecast period due to increasing awareness, growing mental health burden, and economic improvements in healthcare access in countries like India and China.

Competitive Scenario:

Key players in the Global Quetiapine Market include AstraZeneca, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals, Accord Healthcare, and Mylan N.V. These companies are focused on launching generic versions, improving drug delivery systems, and expanding to emerging markets.

Recent developments include:

In 2024, Dr. Reddy’s launched a new low-dose formulation aimed at elderly patients in India.

Teva Pharmaceuticals entered a licensing agreement with a European biotech firm in 2023 to develop a transdermal delivery system for quetiapine.

In 2023, AstraZeneca initiated real-world studies on the long-term safety of extended-release quetiapine in adolescents with bipolar disorder.

Scope of Work – Global Quetiapine Market

Report Metric Details

Market Size (2023) USD 7.1 billion

Projected Market Size (2031) USD 11.4 billion

CAGR (2023–2031) 6.1%

Market Segments By System Type (IR, XR), By End-use (Hospitals, Retail)

Growth Drivers Rising mental illness prevalence, geriatric population growth, off-label use

Opportunities Growth in emerging markets, new delivery technologies

Key Market Developments:

2024: Dr. Reddy’s introduced low-dose formulations targeted at geriatric patients with enhanced safety profiles.

2023: AstraZeneca launched real-world study initiatives on long-term efficacy and safety.

2023: Teva collaborated with a biotech firm to innovate quetiapine transdermal delivery methods.

FAQs:

1) What is the current market size of the Global Quetiapine Market?

The Global Quetiapine Market was valued at USD 7.1 billion in 2023.

2) What is the major growth driver of the Global Quetiapine Market?

The major growth driver is the rising prevalence of mental health disorders and the expansion of the geriatric population.

3) Which is the largest region during the forecast period in the Global Quetiapine Market?

North America is the largest region due to its advanced healthcare infrastructure and high diagnosis rates.

4) Which segment accounted for the largest market share in the Global Quetiapine Market?

The Extended-Release (XR) segment held the largest share in 2023 due to better compliance and reduced side effects.

5) Who are the key market players in the Global Quetiapine Market?

Key players include AstraZeneca, Teva Pharmaceuticals, Dr. Reddy’s Laboratories, Sun Pharma, and Mylan N.V.